• news.cision.com/
  • CLS/
  • Clinical Laserthermia Systems publishes prospectus relating to the rights issue of units

Clinical Laserthermia Systems publishes prospectus relating to the rights issue of units

Report this content

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED BY SWEDISH LAW. PLEASE SEE "IMPORTANT INFORMATION" AT THE END OF THIS PRESS RELEASE.

Today, June 12, 2023, Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") publishes the prospectus relating to the Company's forthcoming rights issue of units of initially a maximum of approximately SEK 135.7 million before issue costs, for which the subscription period begins on Monday, June 19, 2023 (the "Rights Issue"). The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority and will be made available on the Swedish Financial Supervisory Authority's website (www.fi.se). The prospectus is also available on the Company's (https://clinicallaser.se/investor-relations/corporate-governance/rights-issue-2023/), Sedermera Corporate Finance AB's (www.sedermera.se), Redeye AB's (www.redeye.se) and Nordic Issuing AB's (www.nordic-issuing.se) respective websites.

Publication of prospectus

 

CLS announced on May 8, 2023, that the board of directors has decided to propose an extraordinary general meeting to resolve on the Rights Issue. On June 8, 2023, the extra general meeting resolved on the Rights Issue in accordance with the Board’s proposal.

 

The prospectus, including complete terms and conditions, has today on June 12, 2023, been approved and registered by the Swedish Financial Supervisory Authority and will be made available on the Swedish Financial Supervisory Authority's website (www.fi.se). The prospectus is also available on the Company's (https://clinicallaser.se/investor-relations/corporate-governance/rights-issue-2023/), Sedermera Corporate Finance AB's (www.sedermera.se), Redeye AB's (www.redeye.se) and Nordic Issuing AB's (www.nordic-issuing.se) respective websites. The prospectus has only been drafted in Swedish.

 

A teaser (in Swedish and English) will be published on the Company's, Sedermera Corporate Finance AB's, Redeye AB's and Nordic Issuing AB's respective website, at the latest in connection with the start of the subscription period.

 

Timetable for the Rights Issue

Last day of trading in the share including the right to receive unit rights:

June 13, 2023

First day of trading in the share excluding the right to receive unit rights:

June 14, 2023

Record date for participation in the Rights Issue:

June 15, 2023

Subscription period:

June 19 – July 3, 2023

Trading in unit rights:

June 19 – June 28, 2023

Announcement of the final outcome of the Rights Issue:

July 4-6, 2023

Trading in paid subscribed units (BTU):

From June 19, 2023, until the Swedish Companies Registration Office has registered the Rights Issue. The last day for trading in BTUs will be announced via a separate press release after the completion of the Rights Issue.

 

Investor presentations

On June 19, 2023, at 17.25-21.00, CLS will participate in Financial Stockholm's investor meeting in Stockholm, where CEO Dan J. Mogren will present the business and the Company's future plans. For registration and more information follow the link https://www.eventbrite.se/e/inbjudan-hotell-anglais-stureplan-med-stefan-folster-anders-haglund-biljetter-654873874387?aff=oddtdtcreator.

 

Advisors

Sedermera Corporate Finance AB and Redeye AB are Joint Lead Managers in connection with the Rights Issue. Markets & Corporate Law Nordic AB is legal advisor and Nordic Issuing AB acts as issuing agent in connection with the Rights Issue.

 

For more information on the Rights Issue, please contact:

Sedermera Corporate Finance AB

Phone: +46 40 615 14 10

E-mail: info@sedermera.se

Website: www.sedermera.se

 

Redeye AB

Phone: +46 (0)8 545 013 30

E-mail: info@redeye.se

Website: www.redeye.se

 

For more information about CLS, please contact:

Dan J Mogren, CEO, Clinical Laserthermia Systems AB (publ)

Phone: +46 (0) 70-590 11 40
E-mail: dan.mogren@clinicallaser.com

 

About CLS

Clinical Laserthermia Systems AB (publ) develops and sells the TRANBERG®|Thermal Therapy Systems, including Thermoguide Workstation and sterile disposables, for minimally invasive treatment of cancer tumors and drug-resistant epilepsy, according to regulatory approvals in the EU and the US. The products are marketed for image-guided laser ablation and used in studies for treatment with imILT®, the Company's interstitial laser thermotherapy for immunostimulatory ablation with potential abscopal effects. CLS is headquartered in Lund and has subsidiaries in Germany, the US and Singapore. CLS is listed on the Nasdaq First North Growth Market under the symbol CLS B. The Certified Advisor (CA) is FNCA Sweden AB, Tel: +46 8 528 00 399. E-mail: info@fnca.se

 

For more information about CLS, please visit the Company's website: clinicallaser.se

 

Important information

This press release does not constitute an offer to acquire, subscribe for or otherwise trade in shares, warrants, unit rights, BTUs or other securities in Clinical Laserthermia Systems AB investors should not subscribe for or acquire any securities other than on the basis of the information in the prospectus that will be made public before the start of the subscription period in the Rights Issue. No action has been taken and no action will be taken to permit an offer to the public in any jurisdiction other than Sweden.

 

This press release may not be released, published or distributed, directly or indirectly, in or into the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, South Korea, Russia, Belarus or in any other jurisdiction where the distribution of this press release would be unlawful. Nor does this press release constitute an offer to sell new shares, warrants, unit rights, BTUs or other securities to any person in a jurisdiction where it would not be permitted to make such an offer to such a person or where such action would require additional prospectus, registration or other measures than under Swedish law. The prospectus, the application form and other documents relating to the Rights Issue may not be distributed in or into any country where such distribution or the Rights Issue requires measures referred to in the previous sentence or where they would be contrary to the rules of such country. Actions contrary to this instruction may constitute a violation of applicable securities laws.

 

Neither shares, warrants, unit rights, BTUs nor any other securities have been or will be registered under the United States Securities Act of 1933 in its current wording (the "Securities Act") or the securities laws of any state or other jurisdiction in the United States and may not be offered, subscribed for, exercised, pledged, sold, resold, assigned, delivered or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of any state or other jurisdiction of the United States.

 

This press release may contain certain forward-looking statements that reflect the Company's current views on future events and financial and operational development. Words such as "intends", " estimates", "expects", "may", "plans", "believes", " anticipates" and other expressions that imply indications or predictions of future developments or trends, and that are not based on historical facts, constitute forward-looking statements. By nature, forward-looking statements involve known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not constitute a guarantee of future results or developments and actual outcomes may differ materially from those expressed in forward-looking statements. Neither the Company nor anyone else undertakes to review, update, confirm or publicly announce any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless required by law or the rules of Nasdaq First North Growth Market.

 

This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.